Something’s off.A report describes an experiment in which green monkeys received laboratory-made clusters of amyloid-beta, a protein studied in Alzheimer’s research. The animals continued to perform without an obvious decline on a shape-memory task for the following year.
Yet cerebrospinal-fluid samples collected 12 months after the final treatment reportedly showed lasting differences from controls, including higher levels of an immune-response protein and changes in proteins associated with nerve-cell connections, blood vessels, and clotting. The striking mismatch is between memory that appeared stable on this one task and molecular signals that persisted after the exposure.
The report stresses that these findings do not mean the monkeys had Alzheimer’s disease, do not show that they will later develop memory problems, and cannot establish that the same changes represent early Alzheimer’s in people. The study was small, involved only female monkeys, and used limited protein analyses and a single memory task.
UNVERIFIED
Feed metadata identifies a report, not independently verified underlying facts.
This is an unverified report. The underlying study claims have not been independently verified here.
